Next Article in Journal
Glucose to Platelet Ratio: A Potential Predictor of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Next Article in Special Issue
Camrelizumab-Induced Isolate Abducens Neuritis: A Rare Ophthalmic Immune-Related Adverse Events
Previous Article in Journal
Characteristics of Microstructural Changes Associated with Glioma Related Epilepsy: A Diffusion Tensor Imaging (DTI) Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Brain Sciences
Volume 12
Issue 9
10.3390/brainsci12091168
brainsci-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature

by
Dongchen Li
1,2,
Li Yang
1,
Feng Bai
1,
Shun Zeng
1 and
Xiaoli Liu
1,*
1
Ophthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun 130000, China
2
Clinical College, Jilin University, Xinmin Street 70, Changchun 130000, China
*
Author to whom correspondence should be addressed.
Brain Sci. 2022, 12(9), 1168; https://doi.org/10.3390/brainsci12091168
Submission received: 20 July 2022 / Revised: 25 August 2022 / Accepted: 26 August 2022 / Published: 31 August 2022
(This article belongs to the Special Issue Dissecting Neuroinflammation and Ocular System)
Browse Figure
Versions Notes

Abstract

:
There are increasing reports that anticancer drugs, especially immunotherapy and specific targeted therapy, can cause uveitis, but it is not fully understood whether the clinical features of this drug-induced uveitis differ from those of other types of uveitis and whether there are differences between these drugs. We retrospectively reviewed the published cases and case series in PubMed, Embase, Web of Science, and Cochrane from January 2011 to October 2020. We analysed the data, including patients’ basic information, medications used, duration of use, time to onset, clinical manifestations, diagnosis, treatment, and prognosis of uveitis. We focused on the differences in uveitis caused by immunotherapy and specific targeted therapy. Altogether 93 cases (43 men, 48 women, and 2 cases whose gender was not mentioned) reported in 55 articles were included in this study. The average age was 59.6 ± 13.5 years. Eighty percent of the patients had bilateral involvement. Sixty cases were caused by immunotherapy (64.5%), and twenty-six were caused by specific targeted therapy (27.9%). No significant difference was found in the mean time from treatment to onset between the two groups. Anticancer drug-induced uveitis can involve all parts of the uvea from anterior to posterior, manifested as anterior chamber flare, anterior chamber cells, papillitis, macular oedema, subretinal fluid, and choroidal effusion. Anterior uveitis (24 cases, 40.0%) was more common in immunotherapy, and intermediate uveitis (8 cases, 30.8%) was more common in specific targeted therapy. The mean LogMAR visual acuity in specific targeted therapy at presentation was lower than in immunotherapy, but it was not statistically significant. Corticosteroid therapy can effectively control uveitis induced by anticancer drugs. However, the survival prognosis was poor. Among the 19 patients with reported cancer prognosis, seven (36.8%) had no cancer progression, eight (42.1%) had further metastases, and four (21.0%) died of cancer. In conclusion, uveitis caused by anticancer drugs involves both eyes and manifests as various types of uveitis. Patients with specific targeted therapy are more likely to have intermediate uveitis and low vision, and immunotherapy patients are more likely to have anterior uveitis. Corticosteroids are effective against uveitis caused by anticancer drugs.

1. Introduction

At present, immunotherapy and targeted therapy have been widely used to treat cancer and greatly extended the life of cancer patients [1,2]. Specific targeted therapies exert antitumour effects by inhibiting abnormally expressed signalling pathways that cause tumorigenesis. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) activate two negative regulatory molecules on the surface of T cells and inhibit the activation of T cells. Antibodies against CTLA-4 and PD-1 can block these two molecules that are highly expressed on the surface of cancer cells, promote T cell activation, and then kill cancer cells. It should not be ignored that a small number of patients who use these anticancer medicines develop immune-related diseases including uveitis [3]. For example, unique ocular toxic events have been observed in patients receiving targeted therapy with MEK inhibitors [4]. More than 60% of patients treated with immunotherapeutic agents have side effects, which are called immune-related adverse events (irAEs) [5,6]. Among them, skin and gastrointestinal tract side effects are the most common. [5] Ocular side effects including uveitis are generally rare but require attention [5]. Bacillus Calmette-Guérin (BCG), which is used to treat bladder tumours, can cause uveitis, endophthalmitis, and a rare form of choroiditis because of an allergic reaction or direct bacterial invasion of the choroid [7]. Prompt recognition of uveitis is critical to the care of patients receiving anticancer drugs including immune checkpoint inhibitors [8]. Until now, it has not been fully understood whether the clinical features of this drug-induced uveitis differ from those of other types of uveitis and whether there are differences between these anticancer drugs. In this paper, we reviewed case reports on anticancer-drugs-induced uveitis from 2011 to 2020 and analysed patient information, clinical manifestations, diagnosis, treatment, and clinical and visual outcomes.

2. Patients and Methods

The search queries “Neoplasms/drug therapy” [Mesh] and “Uveitis” were used to search for articles in PubMed, Embase, Web of Science, and Cochrane. The literature from January 2011 to October 2020 was included. The studies were included only if there was a clinical diagnosis of uveitis related to anticancer drugs. If the diagnosis was in doubt, no diagnosis was made, there was no clear relationship between uveitis and anticancer drugs, or the patient had another systemic immune disease, the paper was excluded (Figure 1). We collected all the basic information, including age and sex of the patient; type of cancer; time to occurrence of uveitis; clinical information of uveitis, including the manifestations under the slit lamp, fundus examination and auxiliary examination; the course of treatment, prognosis, and whether the use of anticancer agents was halted. The anatomical classification was conducted according to the standardisation of uveitis nomenclature (SUN) as anterior uveitis, intermediate uveitis, posterior uveitis, or panuveitis [9]. The patient’s visual acuity was converted to a logarithm of the minimum angle of resolution (LogMAR). The hand motion record was 3.0, the light perception record was 4.0, and the no light perception record was 5.0. To study the clinical features of uveitis caused by different anticancer drugs, we divided all cases into three groups, immunotherapy, specific targeted therapy, and other anticancer drugs. The clinical characteristics of uveitis in patients were described by calculating the frequency of each feature in these cases. Chi-square and Fisher exact tests (Software SPSS Statistics 28.0, International Business Machines Corporation, New York, NY, USA) were used to compare the differences in uveitis between the immunotherapy and specific targeted therapy groups. Independent sample t-tests were used to compare the visual acuity at presentation and the time from treatment to onset between the two groups. p values of less than 0.05 were considered statistically significant. This study met the requirements of the Declaration of Helsinki and was approved by the Clinical Ethics Committee.

3. Results

3.1. Epidemiology

From 2011 to 2020, 93 cases of uveitis were reported in 55 articles [1,2,3,4,5,6,7,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57]. Among them, there were 43 men (46.9%) and 48 women (50.6%). The average age was 59.2 ± 12.8 years, with a range of 7–92 years. The average age of the men was 59.1 ± 11.1 years and of the women was 59.3 ± 14.5 years. There were two 60-year-old patients whose gender was not mentioned.

3.2. Aetiology

Uveitis was caused by immunotherapy (60 cases, 64.5%) and specific targeted therapy (26 cases, 27.9%). Immunotherapy-induced uveitis involved anti-PD-1 agents (pembrolizumab (23 cases, 24.7%) and nivolumab (13 cases, 14.0%)) and T-lymphocyte antigen-4 (ipilimumab (18 cases, 19.4%) plus ipilimumab and nivolumab (6 cases, 6.5%)). Specific targeted therapies included BRAF inhibitor vemurafenib (12 cases, 13.0%); MEK inhibitors (XL518 (3 cases, 3.2%) and encorafenib and binimetinib (1 case, 1.1%)); BRAF inhibitor combined with MEK inhibitor (trametinib and dabrafenib (6 cases, 6.5%)); inhibitor of epidermal growth factor receptor tyrosine kinase (erlotinib (3 cases, 3.2%)); and C-kit inhibitor (nilotinib (1 case, 1.1%)). In addition, the BCG vaccine used for bladder cancer (6 cases, 6.5%) might also have caused uveal inflammation. Uveitis had also been reported with anastrozole prescribed for breast cancer (1 case, 1.1%). The indications for anticancer drugs to treat cancer are shown in Table 1.

3.3. Clinical Character

Eighty-four per cent of patients had bilateral involvement. Both eyes were simultaneously affected in 80.0% of patients in the immunotherapy group and in 84.6% of patients in the specific targeted therapy group. The time span from treatment to onset was wide-ranging, with the mean time of 13.8 ± 19.4 weeks for the immunotherapy group, 22.8 ± 22.5 weeks for nivolumab, and 15.3 ± 22.8 weeks for pembrolizumab. The time span from treatment to onset for the specific targeted therapy group was longer, with the mean time of 21.6 ± 22.7 weeks and 39.9 ± 38.6 weeks for vemurafenib. The average with BCG was 11.17 ± 7.67 weeks. Patients developed uveitis more than two years after using anastrozole.
Visual acuity was recorded in 52 patients (55.9%), and the mean LogMAR acuity was 0.48 ± 0.94 at presentation. The mean LogMAR visual acuity of the immunotherapy and specific targeted therapy groups was 0.34 ± 0.47 and 0.74 ± 1.38, respectively. Of the 18 patients with recorded IOP, 3 had elevated IOP (>21 mmHg). One ipilimumab patient had 35 mmHg in the right eye and 43 mmHg in the left eye [5], and one nivolumab patient had elevated IOP [41]. One patient developed elevated intraocular pressure secondary to the pupil block due to vemurafenib [48]. Three patients had an IOP of less than or equal to 10 mmHg: two patients receiving pembrolizumab had an IOP of 6 mmHg and 8 mmHg [15,38], respectively, and one patient receiving BCG had an IOP of 10 mmHg [46]. The average intraocular pressure was 16.32 ± 11.97 mmHg.
Decreased vision was the most common initial symptom. In the immunotherapy group, nearly 28.3% of the patients’ first visit was due to decreased vision, while in the specific targeted therapy group, it was 53.9%. Statistical analysis showed that it was significantly higher in the specific targeted therapy group than in the immunotherapy group. Other ocular manifestations, such as redness and eye pain (19.2%) and floaters (7.7%), were found in both two groups. A total of 16.7% of the cases were accompanied by systemic manifestations in the immunotherapy group, of which VKH-like systemic manifestations were the most common (40.0%), while 11.5% of patients had systemic manifestations in the specific targeted therapy group. Both groups could involve all parts of the uvea from anterior to posterior. Intermediate uveitis (8 cases, 30.8%) was more common in specific targeted therapy (p < 0.05). In terms of fundus changes, papillitis (18.3% and 7.7%), retinal detachment (8.3% and 23.1%), and macular oedema (15.0% and 15.4%) occurred in the immunotherapy and specific targeted therapy groups, respectively, and no significant difference was found. In the immunotherapy group, the most common causes of uveitis were pembrolizumab (23, 24.7%) and ipilimumab (18, 19.4%). In the specific targeted therapy group, the most common cause of uveitis was vemurafenib, which was dominated by ocular symptoms and signs of the anterior segment. Changes in the fundus were mainly macular oedema (Table 2, Table 3 and Table 4).

3.4. Treatment

Of the 91 patients with treatment records, in 36 cases (39.6%) it was chosen to discontinue medication. Anti-inflammatory therapy was the first option considered, and 79 patients were treated with steroids, of which 44 patients (55.7%) were treated with topical therapy, 16 patients (20.3%) were treated with a combination of topical and systemic therapy, and 18 patients (22.8%) were treated with systemic therapy. Prednisolone was the most commonly used drug in systemic therapy (15 cases, 18.9%). Prednisone acetate was the most commonly used drug in topical therapy (12 cases, 15.2%). Other corticosteroids included dexamethasone (11 cases, 13.9%), methylprednisolone (11 cases, 13.9%), triamcinolone acetonide (7 cases, 8.9%), and betamethasone (3 cases, 3.8%). Another 12 patients selected other anti-inflammatory agents: seven patients received difluprednate, a difluorinated derivative of prednisolone that has strong anti-inflammatory activity; four patients received topical virostatic drug such as acyclovir for one month; non-steroidal anti-inflammatory drugs such as bromfenac sodium were also used in anti-inflammatory treatment.
In addition to receiving anti-inflammatory treatment, patients with different symptoms received different treatments. If posterior synechiae were present (4 cases), atropine (2 cases), scopolamine (1 case), or cyclopentolate (1 case) might be used. At the same time, subconjunctival injection of sympathetic agents (2 cases) could rupture the adhesion. Patients with an elevated IOP may be treated with IOP-lowering agents [5], and one patient with an IOP over 50 mmHg received intravenous mannitol [36]. An intravitreal injection of ranibizumab could be used to treat choroidal neovascularisation secondary to multifocal choroiditis [13]. Some patients with bladder cancer who received BCG developed an ocular inflammation with cystic macular oedema (CME) and submacular fluid [31]. After other possible causes were ruled out, it was decided to start 2 months of anti-tuberculous therapy (ATT) with isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (1200 mg/day), and inflammation rapidly decreased to 0+, and macular degeneration subsided at 3 weeks [31]. However, it is worth noting that if the pupillary block caused by posterior synechiae was too severe, surgical peripheral iridectomy was required.

3.5. Prognosis

The majority of patients had a good prognosis, and uveitis was cured in an average of 3.6 ± 4.4 months after treatment. Only two patients had recurrent uveitis without discontinuation of the medication. In contrast with the prognosis for uveitis, the patient’s cancer prognosis was poor. Of the 19 cases reported, only seven cases (36.8%) had no cancer progression, eight cases (42.1%) had further metastasis, and four cases (21.0%) died of cancer shortly thereafter. Of the 19 patients with documented survival outcomes, 12 discontinued anticancer drugs because of uveitis, and their survival outcomes were worse, with 67% having further cancer progression or death. A patient with choroidal melanoma of the right eye for more than 3 years died of progressive metastatic omental disease 6 weeks after the onset of uveitis. A patient with metastatic cutaneous melanoma for over 8 months died of systemic complications of metastatic melanoma 6 months after uveitis. A patient with stage IV squamous cell cancer of the left lung for 15 months with liver metastasis died 7 months after the onset of uveitis. A patient with a four-year malignant melanoma course died four months after uveitis.

4. Discussion

The management of uveitis in patients treated with anticancer drugs is complex. One major challenge was to determine whether uveitis was caused by the oncologic treatment or by other possible causes. Uveitis caused by anticancer drugs could be inferred from chronological order. For example, ocular and systemic symptoms occurred simultaneously after 5 weeks of erlotinib treatment [30]. Bilateral uveitis and papillitis started after 2 months of pembrolizumab treatment and improved significantly after discontinuation and initiation of topical steroid therapy. When pembrolizumab was restarted, bilateral uveitis recurred [11]. Other causes of uveitis could be ruled out by extensive examination. Multimodal imaging using optical coherence tomography (OCT), fundus fluorescein angiography (FA), and indocyanine green angiography (ICGA) could provide detailed ocular features of uveitis. Blood tests were also used to screen for the cause of uveitis.
The clinical features of uveitis caused by anticancer drugs were related to the drugs used, regardless of the age or sex of the patients. More than 95% of patients presented with simultaneous uveitis in both eyes. Immunotherapy and specific targeted therapy can cause panuveitis, manifested as anterior chamber flare, anterior chamber cells, papillitis, macular oedema, and subretinal fluid. In both groups, choroidal effusion had been reported. However, patients in the targeted drug treatment group were more likely to experience decreased vision, redness, and pain. This was associated with higher rates of posterior synechiae and serous retinal detachment in the targeted drug group. It was suggested that uveitis induced by specific targeted therapy might be more serious. The time span from the initiation of anticancer drugs to the appearance of uveitis was slightly longer in the specific targeted therapy group, especially for vemurafenib, reaching 32.78 ± 32.14 weeks. Ipilimumab was more likely to cause uveitis, with uveitis occurring after an average of 4.31 ± 3.15 weeks. The immunotherapy group was more prone to systemic changes such as VKH-like vitiligo [17]. Every patient (no matter if the patient was on immune or specific targeted therapy) must be examined completely, both with anterior and posterior segment examinations.
The treatment of uveitis induced by anticancer drugs needs to be determined on a case-by-case basis. The most commonly used drugs for treatment were steroids. Severe episodes of uveitis may require withdrawal and systemic corticosteroid treatment, such as short-term intravenous methylprednisolone, followed by oral prednisolone. However, most patients had mild uveitis, and systemic corticosteroids were not recommended because of tumour therapy, so topical corticosteroids such as topical prednisone 1% acetate drops (eight times per day) should be used. If there was no active disease and vision was normal, routine monitoring of uveitis was recommended, and corticosteroid treatment might be appropriately postponed. Nonsteroidal anti-inflammatory drugs (bromfenac sodium) can be used to control inflammation [2]. Others include symptomatic treatment. Mydriatic drugs were used to prevent and treat posterior synechiae. For patients with elevated intraocular pressure, intraocular pressure-lowering drugs should be concomitantly used. When choroidal neovascularisation was present, intravitreal injection of anti-VEGF agents such as ranibizumab should be performed. Some patients with bladder cancer who receive BCG injections may be treated with anti-tuberculous treatment after other possible causes have been ruled out [31].
In conclusion, anticancer drugs, including both immunotherapy and specific targeted therapy, could induce uveitis. There is no statistically significant difference in the time interval from the start of medication to the appearance of uveitis between the two groups. Uveitis caused in either of the two groups might be accompanied by systemic changes. Both therapies can cause various fundus changes, including serous retinal detachment. After symptomatic treatment using corticosteroids, most patients with uveitis have a good prognosis. Given that anticancer drugs can induce uveitis, it is recommended that patients taking these drugs should be routinely screened by a uveitis specialist.

Author Contributions

D.L.: data collection and analysis, and writing of the manuscript. L.Y., F.B. and S.Z.: data collection, analysis, and editing of the manuscript. X.L.: acquisition of funding, supervision and planning of the study, data analysis, and writing of the manuscript. All authors contributed to the article and approved the submitted version. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China, Grant No. 81300752, the Jilin Province Science and Technology Development Plan Project, Grant No. 20200201333JC, and the Jilin Province Health Special Project, Grant No. 2020SCZT058.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors have no conflict of interest to declare.

References

  1. Conrady, C.D.; LaRochelle, M.; Pecen, P.; Palestine, A.; Shakoor, A.; Singh, A. Checkpoint inhibitor-induced uveitis: A case series. Graefe’s Arch. Clin. Exp. Ophthalmol. 2018, 256, 187–191. [Google Scholar] [CrossRef]
  2. Diem, S.; Keller, F.; Rüesch, R.; Maillard, S.A.; Speiser, D.E.; Dummer, R.; Siano, M.; Urner-Bloch, U.; Goldinger, S.M.; Flatz, L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy? J. Immunother. 2016, 39, 379–382. [Google Scholar] [CrossRef] [PubMed]
  3. Chan, S.; Ahern, E.; Chaudhry, S.; Hughes, B. Bilateral acute anterior uveitis: A rare ocular side effect of erlotinib. BMJ Case Rep. 2019, 12, e232868. [Google Scholar] [CrossRef]
  4. McCannel, T.A.; Chmielowski, B.; Finn, R.S.; Goldman, J.; Ribas, A.; Wainberg, Z.A.; McCannel, C.A. Bilateral Subfoveal Neurosensory Retinal Detachment Associated with MEK Inhibitor Use for Metastatic Cancer. JAMA Ophthalmol. 2014, 132, 1005–1009. [Google Scholar] [CrossRef]
  5. Fierz, F.C.; Meier, F.; Chaloupka, K.; Böni, C. Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma—Case Series and Review. Klin Monbl Augenheilkd. 2016, 233, 540–544. [Google Scholar] [CrossRef] [PubMed]
  6. Crosson, J.N.; Laird, P.W.; Debiec, M.; Bergstrom, C.S.; Lawson, D.H.; Yeh, S. Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition with Ipilimumab for Metastatic Melanoma. J. Immunother. 2015, 38, 80–84. [Google Scholar] [CrossRef]
  7. Parafita-Fernández, A.; Parafita, M.A. Bilateral Iritis after Vaccine for Bladder Cancer. Optom. Vis. Sci. 2015, 92, e368–e370. [Google Scholar] [CrossRef]
  8. Dow, E.R.; Yung, M.; Tsui, E. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. Ocul. Immunol. Inflamm. 2021, 29, 203–211. [Google Scholar] [CrossRef]
  9. Jabs, D.A.; Nussenblatt, R.B.; Rosenbaum, J.T. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am. J. Ophthalmol. 2005, 140, 509–516. [Google Scholar] [CrossRef]
  10. Aaberg, M.T.; Aaberg, T.M. Pembrolizumab Administration Associated with Posterior Uveitis. Retin. Cases Brief Rep. 2017, 11, 348–351. [Google Scholar] [CrossRef]
  11. Abu Samra, K.; Valdes-Navarro, M.; Lee, S.; Swan, R.; Foster, C.S.; Anesi, S.D. A Case of Bilateral Uveitis and Papillitis in a Patient Treated with Pembrolizumab. Eur. J. Ophthalmol. 2016, 26, e46–e48. [Google Scholar] [CrossRef] [PubMed]
  12. Acaba-Berrocal, L.A.e.a. Birdshot-like Chorioretinopathy Associated with Pembrolizumab Treatment. JAMA Ophthalmol. 2018, 136, 1205–1207. [Google Scholar] [CrossRef] [PubMed]
  13. Albertini, G.C.; Corbelli, E.; Parodi, M.B.; Bandello, F. Choroidal Neovascularization in Multifocal Choroiditis after Dabrafenib and Trametinib. Eur. J. Ophthalmol. 2017, 27, e184–e186. [Google Scholar] [CrossRef] [PubMed]
  14. Arai, T.; Harada, K.; Usui, Y.; Irisawa, R.; Tsuboi, R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J. Dermatol. 2016, 44, 975–976. [Google Scholar] [CrossRef] [PubMed]
  15. Basilious, A.; Lloyd, J.C. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report. Can. J. Ophthalmol. 2016, 51, e4–e6. [Google Scholar] [CrossRef] [PubMed]
  16. Bickel, A.; Koneth, I.; Enzler-Tschudy, A.; Neuweiler, J.; Flatz, L.; Früh, M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer 2016, 16, 656. [Google Scholar] [CrossRef]
  17. Brambati, M.; Giuffrè, C.; Marchese, A.; Bandello, F.; Modorati, G.M.; Miserocchi, E. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma. Eur. J. Ophthalmol. 2020, 32, NP109–NP113. [Google Scholar] [CrossRef]
  18. Bricout, M.; Petre, A.; Amini-Adle, M.; Bezza, W.; Seve, P.; Kodjikian, L.; Dalle, S.; Thomas, L. Vogt-Koyanagi-Harada–like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma. J. Immunother. 2017, 40, 77–82. [Google Scholar] [CrossRef]
  19. Cugati, S.; Gilhotra, J.S.; Lake, S.; Gordon, D.L. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma. Clin. Exp. Ophthalmol. 2013, 42, 494–495. [Google Scholar] [CrossRef]
  20. Di Giacomo, A.M.; Biagioli, M.; Maio, M. The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications. Semin. Oncol. 2010, 37, 499–507. [Google Scholar] [CrossRef]
  21. Diamantopoulos, P.T.; Stoungioti, S.; Anastasopoulou, A.; Papaxoinis, G.; Gogas, H. Incomplete Vogt–Koyanagi–Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. Melanoma Res. 2018, 28, 648–651. [Google Scholar] [CrossRef] [PubMed]
  22. Fonollosa, A.; Mesquida, M.; Adán, A. Uveitic macular oedema after treatment with vemurafenib. Acta Ophthalmol. 2015, 93, e686–e687. [Google Scholar] [CrossRef] [PubMed]
  23. Fujiwara, R.; Inamura, K.; Yuasa, T.; Numao, N.; Yamamoto, S.; Masuda, H.; Kawauchi, A.; Takeuchi, K.; Yonese, J. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. Int. J. Clin. Oncol. 2019, 25, 151–157. [Google Scholar] [CrossRef] [PubMed]
  24. Fusumae, T.; Kamiya, K.; Maekawa, T.; Komine, M.; Murata, S.; Inoda, S.; Takahashi, R.; Kawashima, H.; Ohtsuki, M. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma. J. Dermatol. 2018, 45, e159–e160. [Google Scholar] [CrossRef] [PubMed]
  25. Guedj, M.; Quéant, A.; Funck-Brentano, E.; Kramkimel, N.; Lellouch, J.; Monnet, D.; Longvert, C.; Gantzer, A.; Brézin, A.P. Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib. JAMA Ophthalmol. 2014, 132, 1421–1425. [Google Scholar] [CrossRef]
  26. Hanna, K.S. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2016, 36, e183–e188. [Google Scholar] [CrossRef]
  27. Kanno, H.; Ishida, K.; Yamada, W.; Nishida, T.; Takahashi, N.; Mochizuki, K.; Mizuno, Y.; Matsuyama, K.; Takahashi, T.; Seishima, M. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. J. Infect. Chemother. 2017, 23, 774–777. [Google Scholar] [CrossRef]
  28. Kirkpatrick, C.A.; Almeida, D.R.; Hornick, A.L.; Chin, E.K.; Boldt, H.C. Erlotinib-associated bilateral anterior uveitis: Resolution with posterior sub-Tenon’s triamcinolone without erlotinib cessation. Can. J. Ophthalmol. 2015, 50, e66–e67. [Google Scholar] [CrossRef]
  29. Lim, J.; Lomax, A.J.; McNeil, C.; Harrisberg, B. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report. Ocul. Immunol. Inflamm. 2018, 26, 628–631. [Google Scholar] [CrossRef]
  30. Lim, L.T.; Blum, R.A.; Cheng, C.P.; Hanifudin, A. Bilateral anterior uveitis secondary to erlotinib. Eur. J. Clin. Pharmacol. 2010, 66, 1277–1278. [Google Scholar] [CrossRef]
  31. Llorenç, V.; Mesquida, M.; Molins, B.; González-Martín, J.; De La Maza, M.S.; Adán, A. Bacillus Calmette–Guérin Infection and Cytotoxicity in the Retinal Pigment Epithelium. Ocul. Immunol. Inflamm. 2018, 26, 786–792. [Google Scholar] [CrossRef] [PubMed]
  32. Marjanska, A.; Galazka, P.; Marjanski, M.; Wysocki, M.; Styczynski, J. Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma. Anticancer Res. 2019, 39, 3945–3947. [Google Scholar] [CrossRef] [PubMed]
  33. Miserocchi, E.; Cimminiello, C.; Mazzola, M.; Russo, V.; Modorati, G.M. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can. J. Ophthalmol. 2015, 50, e2–e4. [Google Scholar] [CrossRef] [PubMed]
  34. Moore, D.C.; Muslimani, A.; Sinclair, P. Nilotinib-Induced Ocular Toxicity: A Case Report. Am. J. Ther. 2018, 25, e570–e571. [Google Scholar] [CrossRef] [PubMed]
  35. Nallapaneni, N.N.; Mourya, R.; Bhatt, V.R.; Malhotra, S.; Ganti, A.K.; Tendulkar, K.K. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J. Natl. Compr. Cancer Netw. 2014, 12, 1077–1081. [Google Scholar] [CrossRef]
  36. Numata, S.; Okumura, R.; Arima, M.; Kobayashi, T.; Watanabe, S.; Suzuki, K.; Horiguchi, M.; Sugiura, K.; Iwata, Y. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report. J. Dermatol. 2018, 45, 113–114. [Google Scholar] [CrossRef]
  37. Papavasileiou, E.; Prasad, S.; Freitag, S.K.; Sobrin, L.; Lobo, A.-M. Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature. Ocul. Immunol. Inflamm. 2016, 24, 140–146. [Google Scholar] [CrossRef]
  38. Reid, G.; Lorigan, P.; Heimann, H.; Hovan, M. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma. Ocul. Immunol. Inflamm. 2018, 27, 1012–1015. [Google Scholar] [CrossRef]
  39. Rueda-Rueda, T.; Sánchez-Vicente, J.; Moruno-Rodríguez, A.; Molina-Socola, F.; Martínez-Borrego, A.; López-Herrero, F. Uveítis y desprendimiento seroso de retina secundarios al tratamiento sistémico con dabrafenib y trametinib. Archivos de la Sociedad Española de Oftalmología 2018, 93, 458–462. [Google Scholar] [CrossRef]
  40. Sathiamoorthi, S.; Ruddy, K.J.; Bakri, S.J. Association of Uveitis and Macular Edema With Anastrozole Therapy. JAMA Ophthalmol. 2018, 136, 837–839. [Google Scholar] [CrossRef]
  41. Sun, M.M.; Levinson, R.D.; Filipowicz, A.; Anesi, S.; Kaplan, H.J.; Wang, W.; M.D., D.A.G.; Gangaputra, S.; Swan, R.T.; Sen, H.N.; et al. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul. Immunol. Inflamm. 2020, 28, 217–227. [Google Scholar] [CrossRef] [PubMed]
  42. Tamura, T.; Akimoto, E.; Matsumoto, C.; Mori, S.; Nishi, T.; Kudo, K.; Kuyama, S. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non–Small Cell Lung Cancer. J. Thorac. Oncol. 2018, 13, 1606–1607. [Google Scholar] [CrossRef]
  43. Tan, A.X.; Ang, A.; Campbell, W.; Fabinyi, D.C. Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma. Clin. Exp. Ophthalmol. 2018, 46, 819–821. [Google Scholar] [CrossRef] [PubMed]
  44. Telfah, M.; Whittaker, T.J.; Doolittle, G.C. Vision loss with pembrolizumab treatment: A report of two cases. J. Oncol. Pharm. Pr. 2019, 25, 1540–1546. [Google Scholar] [CrossRef] [PubMed]
  45. Theillac, C.; Straub, M.; Breton, A.-L.; Thomas, L.; Dalle, S. Bilateral uveitis and macular edema induced by Nivolumab: A case report. BMC Ophthalmol. 2017, 17, 1–4. [Google Scholar] [CrossRef]
  46. Uppal, G.S.; Shah, A.N.; Tossounis, C.M.; Tappin, M.J. Bilateral Panuveitis following Intravesical BCG Immunotherapy for Bladder Carcinoma. Ocul. Immunol. Inflamm. 2010, 18, 292–296. [Google Scholar] [CrossRef]
  47. Wang, W.; Lam, W.-C.; Chen, L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 2019, 68, 85–95. [Google Scholar] [CrossRef]
  48. Wolf, S.E.J.; Meenken, C.; Moll, A.C.; Haanen, J.B.; Van Der Heijden, M.S. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer 2013, 13, 561. [Google Scholar] [CrossRef]
  49. Yeh, O.L.; Francis, C.E. Ipilimumab-Associated Bilateral Optic Neuropathy. J. Neuro-Ophthalmology 2015, 35, 144–147. [Google Scholar] [CrossRef]
  50. Apivatthakakul, A.; Kunavisarut, P.; Rothova, A.; Pathanapitoon, K. Development of Acute Vogt–Koyanagi–Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma. Ocul. Immunol. Inflamm. 2020, 28, 505–508. [Google Scholar] [CrossRef]
  51. Boiché, M.; Conart, J.-B.; Angioi-Duprez, K. Panuvéite sévère liée à un traitement par vemurafenib pour un mélanome cutané métastatique. J. Français d Ophtalmol. 2018, 41, e291–e292. [Google Scholar] [CrossRef] [PubMed]
  52. Dolaghan, M.J.; Oladipo, B.; Cooke, C.A.; McAvoy, C.E. Metastatic melanoma and immunotherapy-related uveitis: An incidence in Northern Ireland. Eye 2019, 33, 1670–1672. [Google Scholar] [CrossRef] [PubMed]
  53. Fujimura, T.; Kambayashi, Y.; Tanita, K.; Sato, Y.; Hidaka, T.; Otsuka, A.; Tanaka, H.; Furudate, S.; Hashimoto, A.; Aiba, S. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J. Dermatol. 2018, 45, 735–737. [Google Scholar] [CrossRef]
  54. Gao, C.Q.; Mithani, R.; Leya, J.; Dawravoo, L.; Bhatia, A.; Antoine, J.; De Alba, F.; Russo, P.A.; Fimmel, C.J. Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guérin therapy: Case report. BMC Infect. Dis. 2011, 11, 260. [Google Scholar] [CrossRef] [PubMed]
  55. Huggins, A.; Adam, M.; Ehmann, D.; Eagle, R.C.; Malloy, B.; Garg, S.J. A Case of Intravesical Bacillus Calmette–Guerin–Related Endophthalmitis and Retinitis Confirmed with Retinal Biopsy. Retin. Cases Brief Rep. 2019, 13, 333–336. [Google Scholar] [CrossRef] [PubMed]
  56. Rémond, A.-L.; Barreau, E.; Le Hoang, P.; Bodaghi, B. Bilateral uveitis associated with nivolumab therapy. J. Français d Ophtalmol. 2018, 41, e91–e94. [Google Scholar] [CrossRef]
  57. Sızmaz, S.; Görkemli, N.; Esen, E.; Demircan, N. A Rare Cause of Uveitis: Vemurafenib. Turk. J. Ophthalmol. 2018, 48, 323–325. [Google Scholar] [CrossRef]
Brainsci 12 01168 g001 550
Figure 1. The flowchart for identification of articles in databases.
Figure 1. The flowchart for identification of articles in databases.
Brainsci 12 01168 g001
Table
Table 1. Indications of tumour drugs mentioned in the literature.
Table 1. Indications of tumour drugs mentioned in the literature.
ClassificationMedicineCancer
ImmunotherapyIpilimumabMetastatic melanoma
NivolumabMetastatic melanoma
Non-small cell lung cancer
Hodgkin’s lymphoma
Bronchial adenocarcinoma
Renal cell carcinoma
PembrolizumabMetastatic melanoma
Non-small cell lung cancer
Ipilimumab and NivolumabMetastatic melanoma
Endometrial cancer
Specific targeted therapyErlotinibNon-small cell lung cancer
Squamous cell cancer
Trametinib and DabrafenibMetastatic melanoma
VemurafenibMetastatic melanoma
NilotinibMyeloid leukaemia
MEK Inhibitor XL518Metastatic melanoma
Myeloid leukaemia
Encorafenb and BinimetinibMetastatic melanoma
OthersBacillus Calmette-GuérinBladder carcinoma
AnastrozoleBreast carcinoma
MEK: mitogen-activated protein kinase kinase.
Table
Table 2. Clinical manifestations of uveitis caused by immunotherapy.
Table 2. Clinical manifestations of uveitis caused by immunotherapy.
Clinical ManifestationsIpilimumabNivolumabPembrolizumabIpi-NivoTotal
Total, n181323660
SexMale, n (%)7 (38.89%)4 (30.77%)13 (56.53%)4 (66.67%)28 (46.67%)
Female, n (%)11 (61.11%)9 (69.23%)8 (34.78%)2 (33.33%)30 (50.00%)
Mean Age, years ± SD56.17 ± 11.8960.15 ± 12.6861.09 ± 15.5857.17 ± 7.6959.02 ± 13.46
Bilateral involvement, n (%)15 (83.33%)11 (84.62%)16 (69.57%)6 (100%)48 (80.00%)
Simultaneous onset of both eyes, n (%)14 (77.78%)10 (76.92%)16 (69.57%)6 (100%)46 (76.67%)
Mean time from the initiation of treatment to onset of uveitis, weeks ± SD4.31 ± 3.1522.83 ± 22.5215.25 ± 22.8311.67 ± 7.9913.82 ± 19.42
First symptomsVision loss, n (%)5 (27.78%)2 (15.38%)10 (43.48%)17 (28.33%)
Red and pain, n (%)3 (16.67%)3 (23.08%)2 (8.70%) 8 (13.33%)
Floaters, n (%)2 (11.11%)1 (7.69%)2 (8.70%) 5 (8.33%)
Visual field defect, n (%)1 (5.56%) 1 (1.67%)
systemic conditionVKH-like systemic manifestations, n (%)1 (5.56%)2 (15.38%)1 (4.35%) 4 (6.67%)
Hypophysitis, n (%)3 (16.67%) 3 (5.00%)
colitis, n (%)1 (5.56%)1 (4.35%) 2 (3.33%)
Autoimmune hepatitis, n (%)1 (5.56%) 1 (1.67%)
pain, n (%)
Anterior segmentposterior synechiae, n (%)2 (11.11%)3 (23.08%)1 (4.35%)1 (16.67%)7 (11.67%)
keratic precipitates, n (%)2 (11.11%)2 (15.38%)1 (4.35%) 5 (8.33%)
fibrin formation, n (%)1 (5.56%)1 (7.69%) 2 (3.33%)
anterior chamber cells, n (%)7 (38.89%)4(30.77%)8 (34.78%)3 (50.00%)22 (36.67%)
anterior chamber flare, n (%)4 (22.22%)3 (23.08%)3 (13.04%)2 (33.33%)12 (20.00%)
Posterior segmentVitritis, n (%)2 (11.11%)4(30.77%)7 (30.43%)3 (50.00%)18 (30.00%)
Choroidal effusion, n (%) 2 (8.70%)2 (3.33%)
Chorioretinopathy, n (%)1 (5.56%) 1 (1.67%)
macular edema, n (%)3 (16.67%)2 (15.38%)4 (17.39%)9 (15.00%)
Papillitis, n (%)1 (5.56%)4 (30.77%)6 (26.09%)11(18.33%)
subretinal fluid, n (%) 1 (7.69%)2 (8.70%)1 (16.67%)4 (6.67%)
Serous retinal detachment, n (%)1 (5.56%)2 (15.38%)2 (8.70%)5 (8.33%)
% Algorithm: The number of cases with positive signs divided by the total number of cases using the drug; SD: Standard Deviation; VKH: Vogt-Koyanagi-Harada Syndrome.
Table
Table 3. Clinical manifestations of uveitis caused by specific targeted therapy.
Table 3. Clinical manifestations of uveitis caused by specific targeted therapy.
Clinical ManifestationsErlotinibTrametinib and DabrafenibVemurafenibNilotinibMEK Inhibitor XL518Encorafenb and BinimetinibTotal
Total, n361213126
SexMale, n (%) 4 (66.67%)6 (50.00%)1 (100%)1 (33.33%) 12 (46.15%)
Female, n (%)3 (100%)2 (33.33%)6 (50.00%) 2 (66.67%)1 (100%)14(53.85%)
Mean Age, years ± SD69 ± 5.8953 ± 12.9155.17 ± 13.957756.67 ± 4.718158.27 ± 13.88
Bilateral involvement, n (%)3 (100%)5 (83.33%)9 (75.00%)1 (100%)3 (100%)1 (100%)22 (84.62%)
Simultaneous onset of both eyes, n (%)3 (100%)5 (83.33%)9 (75.00%)1 (100%)3 (100%)1 (100%)22(84.62%)
Mean time from the initiation of treatment to onset of uveitis, weeks ± SD68.25 ± 5.7939.91 ± 38.64242 ± 1.412421.62 ± 22.73
First symptomsVision loss, n (%)1 (33.33%)4 (66.67%)6 (50.00%)1 (100%)1 (33.33%)1 (100%)14 (53.85%)
Red and pain, n (%)1 (33.33%) 4 (33.33%) 5 (19.23%)
Floaters, n (%)1 (33.33%) 1 (8.33%) 2 (7.69%)
Visual field defect, n (%)
systemic conditionVKH-like systemic manifestations, n (%) 1 (8.33%) 1 (100%)2 (7.69%)
Hypophysitis, n (%)
colitis, n (%)
Autoimmune hepatitis, n (%)
pain, n (%)1 (33.33%) 1(3.85%)
Anterior segmentposterior synechiae, n (%) 2 (33.33%)4 (33.33%) 6 (23.08%)
keratic precipitates, n (%)1 (33.33%)2 (33.33%)1 (8.33%) 1 (100%)5 (19.23%)
fibrin formation, n (%)
anterior chamber cells, n (%)1 (33.33%)2 (33.33%)5 (41.67%) 8 (30.77%)
anterior chamber flare, n (%)1 (33.33%) 1 (3.85%)
Posterior segmentVitritis, n (%)1 (33.33%)2 (33.33%)3 (25.00%) 6 (23.08%)
Choroidal effusion, n (%)
Chorioretinopathy, n (%)
macular edema, n (%) 4 (33.33%) 4 (15.38%)
Papillitis, n (%) 1 (16.67%)1 (8.33%) 2 (7.69%)
subretinal fluid, n (%) 2 (33.33%)1 (8.33%) 3 (11.54%)
Serous retinal detachment, n (%) 1 (16.79%)2 (16.67%) 2 (66.66%)1 (100%)6 (23.08%)
% algorithm: The number of cases with positive signs divided by the total number of cases using the drug.
Table
Table 4. Comparison of clinical features of uveitis induced by immunotherapy and specific targeted therapy.
Table 4. Comparison of clinical features of uveitis induced by immunotherapy and specific targeted therapy.
CharacteristicsImmunotherapy (n = 60)Percent (%)Specific Targeted Therapy (n = 26)Percent (%)p-Value
Chi-Square TestFisher Exact
Test		Independent-Samples T Test
SexMale
Female
No/Unknown		28
30
2		46.7
50.0
3.3		12
14
0		46.2
53.9
0.0		0.8570.523
Age<60 years
≥60 years		28
32		46.7
53.3		12
14		46.2
53.9		0.9650.577
Bilateral involvementYes
No		48
12		80.0
20.0		22
4		84.6
15.4		0.6130.430
Average onset time
(weeks ± SD)		 13.8 ± 19.4 21.6 ± 22.7 0.165
Average visual acuity at visit
(n ± SD)		 0.3 ± 0.5 0.7 ± 1.4 0.107
Type of uveitisAnterior2440.0830.80.4160.286
Intermediate23.3830.80.001<0.001
Posterior813.3311.50.8191.000
Panuveitis1728.3415.40.1990.156
First symptomsVision loss1728.31557.70.0100.010
Red and pain813.3623.10.4200.207
Floaters58.3311.50.9480.456
Visual field defect11.700.00.5080.698
Systemic conditionVKH-like systemic manifestations46.727.70.8640.591
Hypophysitis35.000.00.2460.550
Colitis23.300.00.3460.484
Autoimmune hepatitis11.700.00.5080.698
Pain00.013.90.1270.302
Anterior segmentPosterior synechiae711.7623.10.3040.152
Keratic precipitates58.3519.20.2790.140
Fibrin formation23.300.00.3460.484
Anterior chamber cells2236.7830.80.5980.393
Anterior chamber flare1220.013.90.1110.097
Posterior segmentVitritis1830.0623.10.5110.352
Choroidal effusion23.300.00.3460.484
Chorioretinopathy11.700.00.5080.698
Macular edema915.0415.40.9641.000
Papillitis1118.327.70.3490.176
Subretinal fluid46.7311.50.7420.356
Serous retinal detachment58.3623.10.1260.067
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Li, D.; Yang, L.; Bai, F.; Zeng, S.; Liu, X. Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature. Brain Sci. 2022, 12, 1168. https://doi.org/10.3390/brainsci12091168

AMA Style

Li D, Yang L, Bai F, Zeng S, Liu X. Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature. Brain Sciences. 2022; 12(9):1168. https://doi.org/10.3390/brainsci12091168

Chicago/Turabian Style

Li, Dongchen, Li Yang, Feng Bai, Shun Zeng, and Xiaoli Liu. 2022. "Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature" Brain Sciences 12, no. 9: 1168. https://doi.org/10.3390/brainsci12091168

APA Style

Li, D., Yang, L., Bai, F., Zeng, S., & Liu, X. (2022). Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature. Brain Sciences, 12(9), 1168. https://doi.org/10.3390/brainsci12091168

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop